Intrepid Financial Planning Group LLC Has $361,000 Holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI)

Intrepid Financial Planning Group LLC cut its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBIFree Report) by 9.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,011 shares of the exchange traded fund’s stock after selling 410 shares during the quarter. Intrepid Financial Planning Group LLC’s holdings in SPDR S&P Biotech ETF were worth $361,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Addison Advisors LLC boosted its position in shares of SPDR S&P Biotech ETF by 27.4% during the 4th quarter. Addison Advisors LLC now owns 535 shares of the exchange traded fund’s stock valued at $48,000 after acquiring an additional 115 shares during the last quarter. Signature Estate & Investment Advisors LLC boosted its position in shares of SPDR S&P Biotech ETF by 5.7% during the 3rd quarter. Signature Estate & Investment Advisors LLC now owns 2,336 shares of the exchange traded fund’s stock valued at $231,000 after acquiring an additional 125 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of SPDR S&P Biotech ETF by 0.6% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 23,873 shares of the exchange traded fund’s stock valued at $2,373,000 after acquiring an additional 148 shares during the last quarter. Invst LLC boosted its position in shares of SPDR S&P Biotech ETF by 6.0% during the 3rd quarter. Invst LLC now owns 2,807 shares of the exchange traded fund’s stock valued at $277,000 after acquiring an additional 160 shares during the last quarter. Finally, Beech Hill Advisors Inc. boosted its position in shares of SPDR S&P Biotech ETF by 2.5% during the 4th quarter. Beech Hill Advisors Inc. now owns 6,655 shares of the exchange traded fund’s stock valued at $599,000 after acquiring an additional 162 shares during the last quarter.

SPDR S&P Biotech ETF Trading Up 1.3 %

Shares of XBI opened at $87.13 on Friday. The company has a market cap of $5.65 billion, a PE ratio of 11.47 and a beta of 0.99. The stock has a 50-day moving average price of $90.06 and a 200-day moving average price of $94.82. SPDR S&P Biotech ETF has a 12-month low of $81.14 and a 12-month high of $105.47.

SPDR S&P Biotech ETF Company Profile

(Free Report)

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Further Reading

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBIFree Report).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.